(MENAFN- GlobeNewsWire - Nasdaq) The HPV testing and Pap test market is set to grow from USD 2.44 billion in 2025 to USD 3.94 billion by 2030, with a CAGR of 10.0%. This growth is fueled by increased awareness of cervical cancer and government-led screening initiatives. Consumables lead the market, driven by demand for reagents and collection kits essential for testing. While cervical cancer screening dominates, vaginal cancer screening is poised for rapid growth, aided by enhanced diagnostic capabilities. The Asia Pacific region is expected to be the fastest-growing market, spurred by improving healthcare infrastructure and public health campaigns. Major players include Hologic, Roche, and BD.Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Human Papilloma Virus/HPV Test and Pap Smear/Test Market by Product & Service, Test Type, Technology, Application, Care Setting, and Region - Global Forecast to 2030" report has been added to ResearchAndMarkets's offering.
The HPV testing and Pap test market is valued at an estimated USD 2.44 billion in 2025 and is projected to reach USD 3.94 billion by 2030, at a CAGR of 10.0%
The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall HPV testing and Pap test market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
![]()
The rising awareness of cervical cancer and the importance of timely screening is significantly boosting the HPV testing and Pap test market. Public health campaigns, government screening initiatives, and educational efforts are making women more informed about the risks associated with HPV infection and the critical role of early detection.
This heightened awareness is leading to greater participation in routine screening programs, directly fueling the demand for both HPV and Pap tests. Support from healthcare providers, advocacy groups, and non-profit organizations further reinforces preventive screening as a key component of women's healthcare. As more women gain access to information and resources about screening, test volumes are expected to rise steadily, driving sustained market growth and strengthening the role of HPV and Pap testing in reducing cervical cancer incidence worldwide.
By product & service, the consumables segment dominated the HPV testing and Pap test market in 2024.
Based on product & service, the HPV testing and Pap test market is segmented into consumables, instruments, and services. In 2024, consumables accounted for the largest share of the market. This dominance is driven by the widespread use of reagents, collection kits, and assay consumables that are essential for both HPV and Pap testing on a recurring basis.
The increasing adoption of HPV screening programs, coupled with the expansion of cervical cancer prevention initiatives, has created steady demand for these products. Consumables play a critical role in ensuring accuracy and reproducibility of test results, which is reinforced by regulatory guidelines that mandate standardized testing protocols. Moreover, the growing shift toward molecular-based HPV assays and automated cytology platforms has further increased the reliance on specialized consumables. The recurring nature of consumable usage, compared to one-time investments in instruments, positions this segment as the largest revenue contributor in the HPV testing and Pap test market.
By application, the vaginal cancer screening segment is projected to achieve the highest growth during the forecast period.
By application, the HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening. While cervical cancer screening currently accounts for the majority of testing volumes due to its high prevalence and established screening guidelines, vaginal cancer screening is expected to witness the fastest growth during the forecast period.
This growth is primarily driven by increasing awareness of vaginal cancers, improvements in diagnostic sensitivity of HPV tests, and a gradual expansion of screening practices beyond cervical cancer. Rising research efforts and clinical recommendations supporting HPV testing for broader gynecologic cancer detection are also contributing to the adoption of vaginal cancer screening. Although it remains a relatively smaller segment today, the potential for early detection and improved patient outcomes is likely to accelerate demand, positioning vaginal cancer screening as a key growth area in the HPV testing and Pap test market.
The Asia Pacific is projected to be the fastest-growing regional market during the forecast period.
The market for HPV testing and Pap tests is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to experience the fastest growth in the HPV testing and Pap test market during the forecast period. Rapid urbanization, improving healthcare infrastructure, and increasing access to diagnostic facilities are expanding screening opportunities across the region.
Government-led initiatives and public health campaigns in countries such as China, India, and Southeast Asian nations are actively promoting cervical cancer awareness and early detection programs. The rising prevalence of HPV infections and growing concerns about women's health are driving the adoption of HPV and Pap testing. Additionally, market players are introducing cost-effective and high-throughput testing solutions tailored to local needs, further accelerating adoption. The combination of expanding healthcare access, regulatory support, and rising patient awareness positions the Asia Pacific as the fastest-growing regional segment in the global HPV testing and Pap test market.
Research Coverage:
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches/approvals in the HPV testing and Pap test market. Market Development: Comprehensive information about lucrative markets across varied regions Market Diversification: Exhaustive information about products, untapped geographies, recent developments, and investments in the HPV testing and Pap test market. Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Hologic, Inc. (US), Becton, Dickinson and Company (BD) (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), and Danaher Corporation (US).
Key Attributes:
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment